You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameTemocapril
Accession NumberDB08836
TypeSmall Molecule
GroupsExperimental, Investigational
DescriptionTemocapril is a prodrug-type angiotensin-I converting enzyme (ACE) inhibitor not approved for use in the United States, but is approved in Japan and South Korea. Temocapril can also be used in hemodialysis patients without risk of serious accumulation.
Structure
Thumb
Synonyms
Temocaprilum
External Identifiers
  • CS-622
Approved Prescription ProductsNot Available
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
AcecolSankyo
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Temocapril hydrochloride
110221-44-8
Thumb
  • InChI Key: XDDQNOKKZKHBIX-ASBZXGSUSA-N
  • Monoisotopic Mass: 512.120641135
  • Average Mass: 513.07
DBSALT000171
Categories
UNII18IZ008EU6
CAS number111902-57-9
WeightAverage: 476.609
Monoisotopic: 476.143963396
Chemical FormulaC23H28N2O5S2
InChI KeyFIQOFIRCTOWDOW-BJLQDIEVSA-N
InChI
InChI=1S/C23H28N2O5S2/c1-2-30-23(29)17(11-10-16-7-4-3-5-8-16)24-18-15-32-20(19-9-6-12-31-19)13-25(22(18)28)14-21(26)27/h3-9,12,17-18,20,24H,2,10-11,13-15H2,1H3,(H,26,27)/t17-,18-,20-/m0/s1
IUPAC Name
2-[(2S,6R)-6-{[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino}-5-oxo-2-(thiophen-2-yl)-1,4-thiazepan-4-yl]acetic acid
SMILES
CCOC(=O)[[email protected]](CCC1=CC=CC=C1)N[[email protected]]1CS[C@@H](CN(CC(O)=O)C1=O)C1=CC=CS1
Pharmacology
IndicationTemocapril is an ACE inhibitor primarily indicated in the treatment of hypertension and congestive heart failure, diabetic nephropathy, and improvement of prognosis for coronary artery diseases (including acute myocardial infarction).
Structured Indications Not Available
PharmacodynamicsTemocapril is a prodrug of its active metabolite (and diacid form) temocaprilat which contains a thiazepine ring. Temocaprilat has slightly higher potency than enalaprilat in ACE inhibition isolated from rabbit lung. ACE inhibitors exert their hemodynamic effect mainly by inhibiting the renin-angiotensin system. They also modulate sympathetic nervous system activity and increase prostaglandin synthesis. They cause mainly vasodilation and mild natriuresis without affecting heart rate and contractility.). When compared with other Angiotensin-converting Enzyme Inhibitors, temocapril's advantages include a rapid onset of action and what research suggests is tighter vascular ACE binding than enalaprilat.
Mechanism of action
TargetKindPharmacological actionActionsOrganismUniProt ID
Angiotensin-converting enzymeProteinunknown
inhibitor
HumanP12821 details
Related Articles
AbsorptionTemocapril is rapidly absorbed in the gastrointestinal tract and converted into the diacid (active) metabolite, which inhibits ACE in plasma.
Volume of distributionNot Available
Protein binding99.5%, including those with renal impairment.
MetabolismNot Available
Route of eliminationTemocapril is eliminated primarily through the liver and kidneys.
Half life13.1 hours in patients with normal liver function.
Clearance

19.4% urinary recovery.

ToxicityIn rats, whether or male or female, the LD50 values of temocapril were higher than 5000 mg/kg.
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategorySMPDB ID
Temocapril Action PathwayDrug actionSMP00733
Temocapril Metabolism PathwayDrug metabolismSMP00732
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE may increase the hypotensive activities of Temocapril.Experimental
AbacavirThe serum concentration of Abacavir can be decreased when it is combined with Temocapril.Approved, Investigational
AcebutololAcebutolol may increase the hypotensive activities of Temocapril.Approved
AceclofenacThe risk or severity of adverse effects can be increased when Temocapril is combined with Aceclofenac.Approved
AcetovanilloneThe risk or severity of adverse effects can be increased when Temocapril is combined with Acetovanillone.Investigational
Acetylsalicylic acidAcetylsalicylic acid may decrease the antihypertensive activities of Temocapril.Approved, Vet Approved
AdapaleneThe risk or severity of adverse effects can be increased when Temocapril is combined with Adapalene.Approved
AlfuzosinThe serum concentration of Alfuzosin can be increased when it is combined with Temocapril.Approved, Investigational
AliskirenAliskiren may increase the hyperkalemic activities of Temocapril.Approved, Investigational
AllopurinolThe risk of a hypersensitivity reaction to Allopurinol is increased when it is combined with Temocapril.Approved
AlogliptinThe risk or severity of adverse effects can be increased when Alogliptin is combined with Temocapril.Approved
AlprazolamThe serum concentration of Alprazolam can be increased when it is combined with Temocapril.Approved, Illicit, Investigational
AlprenololAlprenolol may increase the hypotensive activities of Temocapril.Approved, Withdrawn
AmbrisentanTemocapril may increase the hypotensive activities of Ambrisentan.Approved, Investigational
Ambroxol acefyllinateThe serum concentration of Ambroxol acefyllinate can be decreased when it is combined with Temocapril.Experimental
AmifostineTemocapril may increase the hypotensive activities of Amifostine.Approved, Investigational
AmilorideAmiloride may increase the hyperkalemic activities of Temocapril.Approved
AmineptineThe serum concentration of Amineptine can be increased when it is combined with Temocapril.Illicit, Withdrawn
AminophyllineThe serum concentration of Aminophylline can be decreased when it is combined with Temocapril.Approved
Aminosalicylic AcidAminosalicylic Acid may decrease the antihypertensive activities of Temocapril.Approved
AmitriptylineThe serum concentration of Amitriptyline can be increased when it is combined with Temocapril.Approved
AmlodipineAmlodipine may increase the hypotensive activities of Temocapril.Approved
AnisodamineThe risk or severity of adverse effects can be increased when Temocapril is combined with Anisodamine.Investigational
AntipyrineThe risk or severity of adverse effects can be increased when Temocapril is combined with Antipyrine.Approved
ApremilastThe risk or severity of adverse effects can be increased when Temocapril is combined with Apremilast.Approved, Investigational
AprotininAprotinin may decrease the antihypertensive activities of Temocapril.Approved, Withdrawn
ArdeparinArdeparin may increase the hyperkalemic activities of Temocapril.Approved, Withdrawn
AtenololAtenolol may increase the hypotensive activities of Temocapril.Approved
AtorvastatinThe serum concentration of Atorvastatin can be increased when it is combined with Temocapril.Approved
AzapropazoneThe risk or severity of adverse effects can be increased when Temocapril is combined with Azapropazone.Withdrawn
AzathioprineTemocapril may increase the myelosuppressive activities of Azathioprine.Approved
AzelastineThe risk or severity of adverse effects can be increased when Temocapril is combined with Azelastine.Approved
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Temocapril.Approved
BalsalazideThe risk or severity of adverse effects can be increased when Temocapril is combined with Balsalazide.Approved, Investigational
BemiparinBemiparin may increase the hyperkalemic activities of Temocapril.Approved
BenazeprilBenazepril may increase the hypotensive activities of Temocapril.Approved, Investigational
BendroflumethiazideBendroflumethiazide may increase the hypotensive activities of Temocapril.Approved
BenmoxinBenmoxin may increase the hypotensive activities of Temocapril.Withdrawn
BenoxaprofenThe risk or severity of adverse effects can be increased when Temocapril is combined with Benoxaprofen.Withdrawn
BepridilBepridil may increase the hypotensive activities of Temocapril.Approved, Withdrawn
BetaxololBetaxolol may increase the hypotensive activities of Temocapril.Approved
BethanidineBethanidine may increase the hypotensive activities of Temocapril.Approved
Betulinic AcidThe risk or severity of adverse effects can be increased when Temocapril is combined with Betulinic Acid.Investigational
BimatoprostBimatoprost may increase the hypotensive activities of Temocapril.Approved, Investigational
BisoprololBisoprolol may increase the hypotensive activities of Temocapril.Approved
BoceprevirThe serum concentration of Temocapril can be decreased when it is combined with Boceprevir.Approved
BosentanBosentan may increase the hypotensive activities of Temocapril.Approved, Investigational
BretyliumBretylium may increase the hypotensive activities of Temocapril.Approved
BrimonidineBrimonidine may increase the hypotensive activities of Temocapril.Approved
BrimonidineBrimonidine may increase the antihypertensive activities of Temocapril.Approved
BromfenacThe risk or severity of adverse effects can be increased when Temocapril is combined with Bromfenac.Approved
BromocriptineThe serum concentration of Bromocriptine can be increased when it is combined with Temocapril.Approved, Investigational
BucillamineThe risk or severity of adverse effects can be increased when Temocapril is combined with Bucillamine.Investigational
BumetanideBumetanide may increase the hypotensive activities of Temocapril.Approved
BupranololBupranolol may increase the hypotensive activities of Temocapril.Approved
CabergolineThe serum concentration of Cabergoline can be increased when it is combined with Temocapril.Approved
CanagliflozinCanagliflozin may increase the hyperkalemic activities of Temocapril.Approved
CandesartanThe risk or severity of adverse effects can be increased when Candesartan is combined with Temocapril.Approved
CandoxatrilCandoxatril may increase the hypotensive activities of Temocapril.Experimental
CaptoprilCaptopril may increase the hypotensive activities of Temocapril.Approved
CarbamazepineThe metabolism of Temocapril can be increased when combined with Carbamazepine.Approved, Investigational
CaroxazoneCaroxazone may increase the hypotensive activities of Temocapril.Withdrawn
CarprofenThe risk or severity of adverse effects can be increased when Temocapril is combined with Carprofen.Approved, Vet Approved, Withdrawn
CarteololCarteolol may increase the hypotensive activities of Temocapril.Approved
CarvedilolCarvedilol may increase the hypotensive activities of Temocapril.Approved, Investigational
CastanospermineThe risk or severity of adverse effects can be increased when Temocapril is combined with Castanospermine.Experimental
CelecoxibThe risk or severity of adverse effects can be increased when Temocapril is combined with Celecoxib.Approved, Investigational
CeliprololCeliprolol may increase the hypotensive activities of Temocapril.Approved, Investigational
CertoparinCertoparin may increase the hyperkalemic activities of Temocapril.Approved
ChloroquineThe risk or severity of adverse effects can be increased when Temocapril is combined with Chloroquine.Approved, Vet Approved
ChlorothiazideChlorothiazide may increase the hypotensive activities of Temocapril.Approved, Vet Approved
ChlorotrianiseneThe serum concentration of Chlorotrianisene can be decreased when it is combined with Temocapril.Withdrawn
ChlorthalidoneChlorthalidone may increase the hypotensive activities of Temocapril.Approved
CilazaprilCilazapril may increase the hypotensive activities of Temocapril.Approved
CiprofloxacinTemocapril may increase the arrhythmogenic activities of Ciprofloxacin.Approved, Investigational
CisaprideThe serum concentration of Cisapride can be increased when it is combined with Temocapril.Approved, Investigational, Withdrawn
ClarithromycinThe therapeutic efficacy of Clarithromycin can be decreased when used in combination with Temocapril.Approved
ClomipramineThe serum concentration of Clomipramine can be increased when it is combined with Temocapril.Approved, Vet Approved
ClonidineClonidine may increase the hypotensive activities of Temocapril.Approved
ClonixinThe risk or severity of adverse effects can be increased when Temocapril is combined with Clonixin.Approved
Conjugated Equine EstrogensThe serum concentration of Conjugated Equine Estrogens can be decreased when it is combined with Temocapril.Approved
CryptenamineCryptenamine may increase the hypotensive activities of Temocapril.Approved
CurcuminThe risk or severity of adverse effects can be increased when Temocapril is combined with Curcumin.Investigational
CyclobenzaprineThe serum concentration of Cyclobenzaprine can be increased when it is combined with Temocapril.Approved
CyclophosphamideThe risk or severity of adverse effects can be increased when Temocapril is combined with Cyclophosphamide.Approved, Investigational
CyclosporineThe serum concentration of Cyclosporine can be increased when it is combined with Temocapril.Approved, Investigational, Vet Approved
CyclothiazideCyclothiazide may increase the hypotensive activities of Temocapril.Approved
D-LimoneneThe risk or severity of adverse effects can be increased when Temocapril is combined with D-Limonene.Investigational
DalteparinDalteparin may increase the hyperkalemic activities of Temocapril.Approved
DapoxetineDapoxetine may increase the orthostatic hypotensive activities of Temocapril.Investigational
DebrisoquinDebrisoquin may increase the hypotensive activities of Temocapril.Approved
DelavirdineThe serum concentration of Delavirdine can be decreased when it is combined with Temocapril.Approved
dersalazinedersalazine may decrease the antihypertensive activities of Temocapril.Investigational
DeserpidineTemocapril may increase the hypotensive activities of Deserpidine.Approved
DesipramineThe serum concentration of Desipramine can be increased when it is combined with Temocapril.Approved
DiazoxideDiazoxide may increase the hypotensive activities of Temocapril.Approved
DiclofenacThe risk or severity of adverse effects can be increased when Temocapril is combined with Diclofenac.Approved, Vet Approved
DienestrolThe serum concentration of Dienestrol can be decreased when it is combined with Temocapril.Approved
DiethylstilbestrolThe serum concentration of Diethylstilbestrol can be decreased when it is combined with Temocapril.Approved
DiflunisalDiflunisal may decrease the antihypertensive activities of Temocapril.Approved
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Temocapril.Approved
DihydralazineTemocapril may increase the hypotensive activities of Dihydralazine.Investigational
DihydroergotamineThe serum concentration of Dihydroergotamine can be increased when it is combined with Temocapril.Approved
DiltiazemThe metabolism of Diltiazem can be decreased when combined with Temocapril.Approved
DorzolamideDorzolamide may increase the hypotensive activities of Temocapril.Approved
DosulepinThe serum concentration of Dosulepin can be increased when it is combined with Temocapril.Approved
DoxazosinDoxazosin may increase the hypotensive activities of Temocapril.Approved
DoxepinThe serum concentration of Doxepin can be increased when it is combined with Temocapril.Approved
DrospirenoneTemocapril may increase the hyperkalemic activities of Drospirenone.Approved
DroxicamThe risk or severity of adverse effects can be increased when Temocapril is combined with Droxicam.Approved
DuvelisibThe risk or severity of adverse effects can be increased when Temocapril is combined with Duvelisib.Investigational
DyphyllineThe serum concentration of Dyphylline can be decreased when it is combined with Temocapril.Approved
E6201The risk or severity of adverse effects can be increased when Temocapril is combined with E6201.Investigational
EbselenThe risk or severity of adverse effects can be increased when Temocapril is combined with Ebselen.Investigational
EfonidipineTemocapril may increase the hypotensive activities of Efonidipine.Approved
EnalaprilEnalapril may increase the hypotensive activities of Temocapril.Approved, Vet Approved
EnalaprilatTemocapril may increase the hypotensive activities of Enalaprilat.Approved
EnfuvirtideThe serum concentration of Enfuvirtide can be increased when it is combined with Temocapril.Approved, Investigational
EnoxaparinEnoxaparin may increase the hyperkalemic activities of Temocapril.Approved
EpirizoleThe risk or severity of adverse effects can be increased when Temocapril is combined with Epirizole.Approved
EplerenoneEplerenone may increase the hyperkalemic activities of Temocapril.Approved
EpoprostenolEpoprostenol may increase the hypotensive activities of Temocapril.Approved
EprosartanThe risk or severity of adverse effects can be increased when Eprosartan is combined with Temocapril.Approved
Ergoloid mesylateThe serum concentration of Ergoloid mesylate can be increased when it is combined with Temocapril.Approved
ErgonovineThe serum concentration of Ergonovine can be increased when it is combined with Temocapril.Approved
ErgotamineThe serum concentration of Ergotamine can be increased when it is combined with Temocapril.Approved
EsmirtazapineThe serum concentration of Esmirtazapine can be increased when it is combined with Temocapril.Investigational
EstradiolThe serum concentration of Estradiol can be decreased when it is combined with Temocapril.Approved, Investigational, Vet Approved
EstramustineThe serum concentration of Estramustine can be decreased when it is combined with Temocapril.Approved
Estrogens, esterifiedThe serum concentration of Estrogens, esterified can be decreased when it is combined with Temocapril.Approved
Estrone sulfateThe serum concentration of Estrone sulfate can be decreased when it is combined with Temocapril.Approved
Etacrynic acidEtacrynic acid may increase the hypotensive activities of Temocapril.Approved
EtanerceptThe risk or severity of adverse effects can be increased when Temocapril is combined with Etanercept.Approved, Investigational
Ethinyl EstradiolThe serum concentration of Ethinyl Estradiol can be decreased when it is combined with Temocapril.Approved
EtodolacThe risk or severity of adverse effects can be increased when Temocapril is combined with Etodolac.Approved, Investigational, Vet Approved
EtofenamateThe risk or severity of adverse effects can be increased when Temocapril is combined with Etofenamate.Approved
EtoricoxibThe risk or severity of adverse effects can be increased when Temocapril is combined with Etoricoxib.Approved, Investigational
EtravirineThe serum concentration of Etravirine can be decreased when it is combined with Temocapril.Approved
Evening primrose oilThe risk or severity of adverse effects can be increased when Temocapril is combined with Evening primrose oil.Approved
EverolimusThe risk or severity of adverse effects can be increased when Everolimus is combined with Temocapril.Approved
exisulindThe risk or severity of adverse effects can be increased when Temocapril is combined with exisulind.Investigational
FelodipineFelodipine may increase the hypotensive activities of Temocapril.Approved, Investigational
FenbufenThe risk or severity of adverse effects can be increased when Temocapril is combined with Fenbufen.Approved
FenoldopamFenoldopam may increase the hypotensive activities of Temocapril.Approved
FenoprofenThe risk or severity of adverse effects can be increased when Temocapril is combined with Fenoprofen.Approved
FloctafenineThe risk or severity of adverse effects can be increased when Temocapril is combined with Floctafenine.Approved, Withdrawn
FlunixinThe risk or severity of adverse effects can be increased when Temocapril is combined with Flunixin.Vet Approved
FlurbiprofenThe risk or severity of adverse effects can be increased when Temocapril is combined with Flurbiprofen.Approved, Investigational
ForasartanThe risk or severity of adverse effects can be increased when Forasartan is combined with Temocapril.Experimental
FosinoprilFosinopril may increase the hypotensive activities of Temocapril.Approved
FurazolidoneFurazolidone may increase the hypotensive activities of Temocapril.Approved, Vet Approved
FurosemideFurosemide may increase the hypotensive activities of Temocapril.Approved, Vet Approved
GarlicThe serum concentration of Temocapril can be decreased when it is combined with Garlic.Approved
GuanabenzGuanabenz may increase the hypotensive activities of Temocapril.Approved
GuanadrelGuanadrel may increase the hypotensive activities of Temocapril.Approved
GuanethidineGuanethidine may increase the hypotensive activities of Temocapril.Approved
GuanfacineGuanfacine may increase the hypotensive activities of Temocapril.Approved, Investigational
HeparinHeparin may increase the hyperkalemic activities of Temocapril.Approved, Investigational
HexamethoniumTemocapril may increase the hypotensive activities of Hexamethonium.Experimental
HexestrolThe serum concentration of Hexestrol can be decreased when it is combined with Temocapril.Withdrawn
HigenamineThe risk or severity of adverse effects can be increased when Temocapril is combined with Higenamine.Investigational
HMPL-004The risk or severity of adverse effects can be increased when Temocapril is combined with HMPL-004.Investigational
HydracarbazineHydracarbazine may increase the hypotensive activities of Temocapril.Approved
HydralazineHydralazine may increase the hypotensive activities of Temocapril.Approved
HydrochlorothiazideHydrochlorothiazide may increase the hypotensive activities of Temocapril.Approved, Vet Approved
HydroflumethiazideHydroflumethiazide may increase the hypotensive activities of Temocapril.Approved
IbuprofenThe risk or severity of adverse effects can be increased when Temocapril is combined with Ibuprofen.Approved
IbuproxamThe risk or severity of adverse effects can be increased when Temocapril is combined with Ibuproxam.Withdrawn
IcatibantIcatibant may decrease the antihypertensive activities of Temocapril.Approved
IloprostIloprost may increase the hypotensive activities of Temocapril.Approved, Investigational
ImidaprilTemocapril may increase the hypotensive activities of Imidapril.Investigational
ImipramineThe serum concentration of Imipramine can be increased when it is combined with Temocapril.Approved
IndapamideIndapamide may increase the hypotensive activities of Temocapril.Approved
IndenololTemocapril may increase the hypotensive activities of Indenolol.Withdrawn
IndomethacinThe risk or severity of adverse effects can be increased when Temocapril is combined with Indomethacin.Approved, Investigational
IndoprofenThe risk or severity of adverse effects can be increased when Temocapril is combined with Indoprofen.Withdrawn
IndoraminTemocapril may increase the hypotensive activities of Indoramin.Withdrawn
IproclozideIproclozide may increase the hypotensive activities of Temocapril.Withdrawn
IproniazidIproniazid may increase the hypotensive activities of Temocapril.Withdrawn
IrbesartanThe risk or severity of adverse effects can be increased when Irbesartan is combined with Temocapril.Approved, Investigational
IronThe risk or severity of adverse effects can be increased when Temocapril is combined with Iron.Approved
Iron DextranThe risk or severity of adverse effects can be increased when Temocapril is combined with Iron Dextran.Approved, Vet Approved
IsocarboxazidIsocarboxazid may increase the hypotensive activities of Temocapril.Approved
IsoxicamThe risk or severity of adverse effects can be increased when Temocapril is combined with Isoxicam.Withdrawn
IsradipineIsradipine may increase the hypotensive activities of Temocapril.Approved
KebuzoneThe risk or severity of adverse effects can be increased when Temocapril is combined with Kebuzone.Experimental
KetanserinTemocapril may increase the hypotensive activities of Ketanserin.Investigational
KetoprofenThe risk or severity of adverse effects can be increased when Temocapril is combined with Ketoprofen.Approved, Vet Approved
KetorolacThe risk or severity of adverse effects can be increased when Temocapril is combined with Ketorolac.Approved
LabetalolLabetalol may increase the hypotensive activities of Temocapril.Approved
LacidipineTemocapril may increase the hypotensive activities of Lacidipine.Approved
Lanthanum carbonateThe serum concentration of Temocapril can be decreased when it is combined with Lanthanum carbonate.Approved
LatanoprostLatanoprost may increase the hypotensive activities of Temocapril.Approved, Investigational
LeflunomideThe risk or severity of adverse effects can be increased when Temocapril is combined with Leflunomide.Approved, Investigational
LercanidipineLercanidipine may increase the hypotensive activities of Temocapril.Approved, Investigational
LinagliptinThe risk or severity of adverse effects can be increased when Linagliptin is combined with Temocapril.Approved
LisinoprilLisinopril may increase the hypotensive activities of Temocapril.Approved, Investigational
LisofyllineThe risk or severity of adverse effects can be increased when Temocapril is combined with Lisofylline.Investigational
LithiumThe serum concentration of Lithium can be increased when it is combined with Temocapril.Approved
LofexidineLofexidine may increase the hypotensive activities of Temocapril.Approved, Investigational
LornoxicamThe risk or severity of adverse effects can be increased when Temocapril is combined with Lornoxicam.Approved
LosartanThe risk or severity of adverse effects can be increased when Losartan is combined with Temocapril.Approved
LovastatinThe serum concentration of Lovastatin can be increased when it is combined with Temocapril.Approved, Investigational
LoxoprofenThe risk or severity of adverse effects can be increased when Temocapril is combined with Loxoprofen.Approved
LumiracoxibThe risk or severity of adverse effects can be increased when Temocapril is combined with Lumiracoxib.Approved, Investigational
MacitentanTemocapril may increase the hypotensive activities of Macitentan.Approved
Magnesium salicylateThe risk or severity of adverse effects can be increased when Temocapril is combined with Magnesium salicylate.Approved
ManidipineTemocapril may increase the hypotensive activities of Manidipine.Approved
MasoprocolThe risk or severity of adverse effects can be increased when Temocapril is combined with Masoprocol.Approved
MebanazineMebanazine may increase the hypotensive activities of Temocapril.Withdrawn
MecamylamineMecamylamine may increase the hypotensive activities of Temocapril.Approved
Meclofenamic acidThe risk or severity of adverse effects can be increased when Temocapril is combined with Meclofenamic acid.Approved, Vet Approved
Mefenamic acidThe risk or severity of adverse effects can be increased when Temocapril is combined with Mefenamic acid.Approved
MeloxicamThe risk or severity of adverse effects can be increased when Temocapril is combined with Meloxicam.Approved, Vet Approved
MesalazineMesalazine may decrease the antihypertensive activities of Temocapril.Approved
MestranolThe serum concentration of Mestranol can be decreased when it is combined with Temocapril.Approved
MetamizoleThe risk or severity of adverse effects can be increased when Temocapril is combined with Metamizole.Withdrawn
MethallenestrilThe serum concentration of Methallenestril can be decreased when it is combined with Temocapril.Experimental
MethyclothiazideMethyclothiazide may increase the hypotensive activities of Temocapril.Approved
MethyldopaMethyldopa may increase the hypotensive activities of Temocapril.Approved
Methylene blueMethylene blue may increase the hypotensive activities of Temocapril.Investigational
MethylphenidateMethylphenidate may decrease the antihypertensive activities of Temocapril.Approved, Investigational
MetipranololMetipranolol may increase the hypotensive activities of Temocapril.Approved
MetolazoneMetolazone may increase the hypotensive activities of Temocapril.Approved
MetoprololMetoprolol may increase the hypotensive activities of Temocapril.Approved, Investigational
MetyrosineTemocapril may increase the hypotensive activities of Metyrosine.Approved
MibefradilMibefradil may increase the hypotensive activities of Temocapril.Withdrawn
MidazolamThe serum concentration of Midazolam can be increased when it is combined with Temocapril.Approved, Illicit
MinaprineMinaprine may increase the hypotensive activities of Temocapril.Approved
MinoxidilMinoxidil may increase the hypotensive activities of Temocapril.Approved
MirtazapineThe serum concentration of Mirtazapine can be increased when it is combined with Temocapril.Approved
MizoribineThe risk or severity of adverse effects can be increased when Temocapril is combined with Mizoribine.Investigational
MoclobemideMoclobemide may increase the hypotensive activities of Temocapril.Approved
MoexiprilMoexipril may increase the hypotensive activities of Temocapril.Approved
MolsidomineMolsidomine may increase the hypotensive activities of Temocapril.Approved
MoxonidineTemocapril may increase the hypotensive activities of Moxonidine.Approved
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Temocapril is combined with Mycophenolate mofetil.Approved, Investigational
Mycophenolic acidThe risk or severity of adverse effects can be increased when Temocapril is combined with Mycophenolic acid.Approved
NabumetoneThe risk or severity of adverse effects can be increased when Temocapril is combined with Nabumetone.Approved
NadololNadolol may increase the hypotensive activities of Temocapril.Approved
NadroparinNadroparin may increase the hyperkalemic activities of Temocapril.Approved
NafamostatThe risk or severity of adverse effects can be increased when Temocapril is combined with Nafamostat.Investigational
NaftifineThe risk or severity of adverse effects can be increased when Temocapril is combined with Naftifine.Approved
NaftopidilTemocapril may increase the hypotensive activities of Naftopidil.Investigational
NaproxenThe risk or severity of adverse effects can be increased when Temocapril is combined with Naproxen.Approved, Vet Approved
NCX 4016The risk or severity of adverse effects can be increased when Temocapril is combined with NCX 4016.Investigational
NebivololNebivolol may increase the hypotensive activities of Temocapril.Approved, Investigational
NefazodoneThe serum concentration of Nefazodone can be increased when it is combined with Temocapril.Approved, Withdrawn
NepafenacThe risk or severity of adverse effects can be increased when Temocapril is combined with Nepafenac.Approved
NialamideNialamide may increase the hypotensive activities of Temocapril.Withdrawn
NicardipineNicardipine may increase the hypotensive activities of Temocapril.Approved
NicorandilNicorandil may increase the hyperkalemic activities of Temocapril.Approved
Niflumic AcidThe risk or severity of adverse effects can be increased when Temocapril is combined with Niflumic Acid.Approved
NiguldipineTemocapril may increase the hypotensive activities of Niguldipine.Experimental
NilvadipineNilvadipine may increase the hypotensive activities of Temocapril.Approved
NimesulideThe risk or severity of adverse effects can be increased when Temocapril is combined with Nimesulide.Approved, Withdrawn
NimodipineNimodipine may increase the hypotensive activities of Temocapril.Approved
NisoldipineNisoldipine may increase the hypotensive activities of Temocapril.Approved
NitrendipineNitrendipine may increase the hypotensive activities of Temocapril.Approved
NitroaspirinNitroaspirin may decrease the antihypertensive activities of Temocapril.Investigational
NitroprussideNitroprusside may increase the hypotensive activities of Temocapril.Approved
NortriptylineThe serum concentration of Nortriptyline can be increased when it is combined with Temocapril.Approved
ObinutuzumabTemocapril may increase the hypotensive activities of Obinutuzumab.Approved
OctamoxinOctamoxin may increase the hypotensive activities of Temocapril.Withdrawn
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Temocapril.Approved, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Temocapril is combined with Olopatadine.Approved
OlsalazineThe risk or severity of adverse effects can be increased when Temocapril is combined with Olsalazine.Approved
OmapatrilatOmapatrilat may increase the hypotensive activities of Temocapril.Investigational
OpipramolThe serum concentration of Opipramol can be increased when it is combined with Temocapril.Investigational
OrgoteinThe risk or severity of adverse effects can be increased when Temocapril is combined with Orgotein.Vet Approved
OxaprozinThe risk or severity of adverse effects can be increased when Temocapril is combined with Oxaprozin.Approved
OxprenololOxprenolol may increase the hypotensive activities of Temocapril.Approved
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Temocapril is combined with Oxyphenbutazone.Withdrawn
ParecoxibThe risk or severity of adverse effects can be increased when Temocapril is combined with Parecoxib.Approved
PargylinePargyline may increase the hypotensive activities of Temocapril.Approved
ParnaparinParnaparin may increase the hyperkalemic activities of Temocapril.Approved
PenbutololPenbutolol may increase the hypotensive activities of Temocapril.Approved, Investigational
PentoliniumPentolinium may increase the hypotensive activities of Temocapril.Approved
PentoxifyllinePentoxifylline may increase the hypotensive activities of Temocapril.Approved, Investigational
PerindoprilPerindopril may increase the hypotensive activities of Temocapril.Approved
PethidineThe risk or severity of adverse effects can be increased when Temocapril is combined with Pethidine.Approved
PhenelzinePhenelzine may increase the hypotensive activities of Temocapril.Approved
PheniprazinePheniprazine may increase the hypotensive activities of Temocapril.Withdrawn
PhenoxybenzaminePhenoxybenzamine may increase the hypotensive activities of Temocapril.Approved
PhenoxypropazinePhenoxypropazine may increase the hypotensive activities of Temocapril.Withdrawn
PhentolaminePhentolamine may increase the hypotensive activities of Temocapril.Approved
PhenylbutazoneThe risk or severity of adverse effects can be increased when Temocapril is combined with Phenylbutazone.Approved, Vet Approved
PimecrolimusThe risk or severity of adverse effects can be increased when Temocapril is combined with Pimecrolimus.Approved, Investigational
PimozideThe serum concentration of Pimozide can be increased when it is combined with Temocapril.Approved
PinacidilPinacidil may increase the hypotensive activities of Temocapril.Withdrawn
PindololPindolol may increase the hypotensive activities of Temocapril.Approved
PiretanidePiretanide may increase the hypotensive activities of Temocapril.Experimental
PirfenidoneThe risk or severity of adverse effects can be increased when Temocapril is combined with Pirfenidone.Investigational
PirlindolePirlindole may increase the hypotensive activities of Temocapril.Approved
PiroxicamThe risk or severity of adverse effects can be increased when Temocapril is combined with Piroxicam.Approved, Investigational
PivhydrazinePivhydrazine may increase the hypotensive activities of Temocapril.Withdrawn
PolythiazidePolythiazide may increase the hypotensive activities of Temocapril.Approved
PrazosinPrazosin may increase the hypotensive activities of Temocapril.Approved
PregabalinThe risk or severity of adverse effects can be increased when Temocapril is combined with Pregabalin.Approved, Illicit, Investigational
PropacetamolThe risk or severity of adverse effects can be increased when Temocapril is combined with Propacetamol.Approved
PropranololPropranolol may increase the hypotensive activities of Temocapril.Approved, Investigational
ProtriptylineThe serum concentration of Protriptyline can be increased when it is combined with Temocapril.Approved
PTC299The risk or severity of adverse effects can be increased when Temocapril is combined with PTC299.Investigational
QuinaprilQuinapril may increase the hypotensive activities of Temocapril.Approved, Investigational
QuinethazoneQuinethazone may increase the hypotensive activities of Temocapril.Approved
QuinineQuinine may increase the hypotensive activities of Temocapril.Approved
RamiprilRamipril may increase the hypotensive activities of Temocapril.Approved
RasagilineRasagiline may increase the hypotensive activities of Temocapril.Approved
RemikirenRemikiren may increase the hypotensive activities of Temocapril.Approved
RescinnamineTemocapril may increase the hypotensive activities of Rescinnamine.Approved
ReserpineReserpine may increase the hypotensive activities of Temocapril.Approved
ResveratrolThe risk or severity of adverse effects can be increased when Temocapril is combined with Resveratrol.Experimental, Investigational
ReviparinReviparin may increase the hyperkalemic activities of Temocapril.Approved
RilmenidineTemocapril may increase the hypotensive activities of Rilmenidine.Investigational
RiociguatThe serum concentration of Riociguat can be increased when it is combined with Temocapril.Approved
RituximabTemocapril may increase the hypotensive activities of Rituximab.Approved
RofecoxibThe risk or severity of adverse effects can be increased when Temocapril is combined with Rofecoxib.Investigational, Withdrawn
RosuvastatinThe serum concentration of Rosuvastatin can be increased when it is combined with Temocapril.Approved
SacubitrilThe risk or severity of adverse effects can be increased when Temocapril is combined with Sacubitril.Approved
SafrazineSafrazine may increase the hypotensive activities of Temocapril.Withdrawn
SalicylamideThe risk or severity of adverse effects can be increased when Temocapril is combined with Salicylamide.Approved
Salicylic acidSalicylic acid may decrease the antihypertensive activities of Temocapril.Approved, Vet Approved
SalsalateThe risk or severity of adverse effects can be increased when Temocapril is combined with Salsalate.Approved
SaprisartanThe risk or severity of adverse effects can be increased when Saprisartan is combined with Temocapril.Experimental
SaralasinThe risk or severity of adverse effects can be increased when Saralasin is combined with Temocapril.Investigational
SaxagliptinThe risk or severity of adverse effects can be increased when Saxagliptin is combined with Temocapril.Approved
SelegilineSelegiline may increase the hypotensive activities of Temocapril.Approved, Investigational, Vet Approved
SelexipagTemocapril may increase the hypotensive activities of Selexipag.Approved
SeratrodastThe risk or severity of adverse effects can be increased when Temocapril is combined with Seratrodast.Approved, Investigational
SildenafilThe serum concentration of Sildenafil can be increased when it is combined with Temocapril.Approved, Investigational
SimeprevirThe serum concentration of Simeprevir can be increased when it is combined with Temocapril.Approved
SimvastatinThe serum concentration of Simvastatin can be increased when it is combined with Temocapril.Approved
SirolimusThe risk or severity of adverse effects can be increased when Sirolimus is combined with Temocapril.Approved, Investigational
SitagliptinThe risk or severity of adverse effects can be increased when Sitagliptin is combined with Temocapril.Approved, Investigational
SitaxentanTemocapril may increase the hypotensive activities of Sitaxentan.Approved, Investigational, Withdrawn
Sodium aurothiomalateThe risk or severity of adverse effects can be increased when Temocapril is combined with Sodium aurothiomalate.Approved
SpiraprilSpirapril may increase the hypotensive activities of Temocapril.Approved
SpironolactoneSpironolactone may increase the hyperkalemic activities of Temocapril.Approved
SRT501The risk or severity of adverse effects can be increased when Temocapril is combined with SRT501.Investigational
St. John's WortThe metabolism of Temocapril can be increased when combined with St. John's Wort.Nutraceutical
SulfasalazineThe risk or severity of adverse effects can be increased when Temocapril is combined with Sulfasalazine.Approved
SulindacThe risk or severity of adverse effects can be increased when Temocapril is combined with Sulindac.Approved
SuprofenThe risk or severity of adverse effects can be increased when Temocapril is combined with Suprofen.Approved, Withdrawn
Synthetic Conjugated Estrogens, AThe serum concentration of Synthetic Conjugated Estrogens, A can be decreased when it is combined with Temocapril.Approved
TacrolimusThe metabolism of Tacrolimus can be decreased when combined with Temocapril.Approved, Investigational
TadalafilTadalafil may increase the antihypertensive activities of Temocapril.Approved, Investigational
TasosartanThe risk or severity of adverse effects can be increased when Tasosartan is combined with Temocapril.Approved
TelmisartanThe risk or severity of adverse effects can be increased when Telmisartan is combined with Temocapril.Approved, Investigational
TemsirolimusThe risk or severity of adverse effects can be increased when Temocapril is combined with Temsirolimus.Approved
TenoxicamThe risk or severity of adverse effects can be increased when Temocapril is combined with Tenoxicam.Approved
TepoxalinThe risk or severity of adverse effects can be increased when Temocapril is combined with Tepoxalin.Vet Approved
TeriflunomideThe risk or severity of adverse effects can be increased when Temocapril is combined with Teriflunomide.Approved
TerlipressinTerlipressin may increase the hypotensive activities of Temocapril.Approved, Investigational
TheophyllineThe serum concentration of Theophylline can be decreased when it is combined with Temocapril.Approved
TianeptineThe serum concentration of Tianeptine can be increased when it is combined with Temocapril.Approved
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Temocapril is combined with Tiaprofenic acid.Approved
TiboloneTemocapril may increase the hypotensive activities of Tibolone.Approved
TicrynafenTicrynafen may increase the hypotensive activities of Temocapril.Withdrawn
TimololTimolol may increase the hypotensive activities of Temocapril.Approved
TinoridineThe risk or severity of adverse effects can be increased when Temocapril is combined with Tinoridine.Investigational
TinzaparinTinzaparin may increase the hyperkalemic activities of Temocapril.Approved
TipranavirThe serum concentration of Temocapril can be decreased when it is combined with Tipranavir.Approved, Investigational
TizanidineTizanidine may increase the hypotensive activities of Temocapril.Approved
TolazolineTolazoline may increase the hypotensive activities of Temocapril.Approved, Vet Approved
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Temocapril is combined with Tolfenamic Acid.Approved
TolmetinThe risk or severity of adverse effects can be increased when Temocapril is combined with Tolmetin.Approved
ToloxatoneToloxatone may increase the hypotensive activities of Temocapril.Approved
TolvaptanTolvaptan may increase the hyperkalemic activities of Temocapril.Approved
TorasemideTorasemide may increase the hypotensive activities of Temocapril.Approved
TrandolaprilTrandolapril may increase the hypotensive activities of Temocapril.Approved
TranilastThe risk or severity of adverse effects can be increased when Temocapril is combined with Tranilast.Approved, Investigational
Trans-2-PhenylcyclopropylamineTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Temocapril.Experimental
TranylcypromineTranylcypromine may increase the hypotensive activities of Temocapril.Approved
TravoprostTravoprost may increase the hypotensive activities of Temocapril.Approved
TreprostinilTreprostinil may increase the hypotensive activities of Temocapril.Approved, Investigational
TriamtereneTriamterene may increase the hyperkalemic activities of Temocapril.Approved
TriazolamThe serum concentration of Triazolam can be increased when it is combined with Temocapril.Approved
TrichlormethiazideTrichlormethiazide may increase the hypotensive activities of Temocapril.Approved, Vet Approved
TrimazosinTemocapril may increase the hypotensive activities of Trimazosin.Experimental
TrimethaphanTrimethaphan may increase the hypotensive activities of Temocapril.Approved
TrimethoprimTrimethoprim may increase the hyperkalemic activities of Temocapril.Approved, Vet Approved
TrimipramineThe serum concentration of Trimipramine can be increased when it is combined with Temocapril.Approved
Trisalicylate-cholineThe risk or severity of adverse effects can be increased when Temocapril is combined with Trisalicylate-choline.Approved
UdenafilUdenafil may increase the antihypertensive activities of Temocapril.Approved, Investigational
UnoprostoneUnoprostone may increase the hypotensive activities of Temocapril.Approved
ValdecoxibThe risk or severity of adverse effects can be increased when Temocapril is combined with Valdecoxib.Investigational, Withdrawn
Valproic AcidThe serum concentration of Valproic Acid can be decreased when it is combined with Temocapril.Approved, Investigational
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Temocapril.Approved, Investigational
VardenafilVardenafil may increase the antihypertensive activities of Temocapril.Approved
VerapamilThe metabolism of Verapamil can be decreased when combined with Temocapril.Approved
VildagliptinThe risk or severity of adverse effects can be increased when Vildagliptin is combined with Temocapril.Approved, Investigational
VinpocetineTemocapril may increase the hypotensive activities of Vinpocetine.Investigational
XylometazolineXylometazoline may increase the hypotensive activities of Temocapril.Approved
YohimbineYohimbine may decrease the antihypertensive activities of Temocapril.Approved, Vet Approved
ZaltoprofenThe risk or severity of adverse effects can be increased when Temocapril is combined with Zaltoprofen.Approved
ZidovudineThe serum concentration of Zidovudine can be decreased when it is combined with Temocapril.Approved
ZileutonThe risk or severity of adverse effects can be increased when Temocapril is combined with Zileuton.Approved, Investigational, Withdrawn
ZomepiracThe risk or severity of adverse effects can be increased when Temocapril is combined with Zomepirac.Withdrawn
Food InteractionsNot Available
References
Synthesis ReferenceNot Available
General References
  1. Tsuji A: Transporter-mediated Drug Interactions. Drug Metab Pharmacokinet. 2002;17(4):253-74. [PubMed:15618677 ]
  2. Furuta S, Kiyosawa K, Higuchi M, Kasahara H, Saito H, Shioya H, Oguchi H: Pharmacokinetics of temocapril, an ACE inhibitor with preferential biliary excretion, in patients with impaired liver function. Eur J Clin Pharmacol. 1993;44(4):383-5. [PubMed:8513851 ]
  3. Nakashima M, Yamamoto J, Shibata M, Uematsu T, Shinjo H, Akahori T, Shioya H, Sugiyama K, Kawahara Y: Pharmacokinetics of temocapril hydrochloride, a novel angiotensin converting enzyme inhibitor, in renal insufficiency. Eur J Clin Pharmacol. 1992;43(6):657-9. [PubMed:1493850 ]
  4. Yasunari K, Maeda K, Nakamura M, Watanabe T, Yoshikawa J, Asada A: Pharmacological and clinical studies with temocapril, an angiotensin converting enzyme inhibitor that is excreted in the bile. Cardiovasc Drug Rev. 2004 Fall;22(3):189-98. [PubMed:15492767 ]
  5. Clearance of Temocapril and Enalapril during Haemodialysis Treatment [Link]
External Links
ATC CodesC09AA14
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSDownload (569 KB)
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9707
Blood Brain Barrier-0.8501
Caco-2 permeable-0.6871
P-glycoprotein substrateSubstrate0.8016
P-glycoprotein inhibitor INon-inhibitor0.6373
P-glycoprotein inhibitor IINon-inhibitor0.9056
Renal organic cation transporterNon-inhibitor0.8744
CYP450 2C9 substrateNon-substrate0.6676
CYP450 2D6 substrateNon-substrate0.8686
CYP450 3A4 substrateSubstrate0.5082
CYP450 1A2 substrateNon-inhibitor0.7748
CYP450 2C9 inhibitorNon-inhibitor0.6996
CYP450 2D6 inhibitorNon-inhibitor0.8016
CYP450 2C19 inhibitorInhibitor0.5371
CYP450 3A4 inhibitorNon-inhibitor0.746
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.7297
Ames testNon AMES toxic0.7962
CarcinogenicityNon-carcinogens0.8965
BiodegradationNot ready biodegradable0.9584
Rat acute toxicity2.3397 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9862
hERG inhibition (predictor II)Inhibitor0.5523
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage formsNot Available
PricesNot Available
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting pointdecomposes at 187Not Available
water solubility<1 mg/mLNot Available
Predicted Properties
PropertyValueSource
Water Solubility0.00342 mg/mLALOGPS
logP2.46ALOGPS
logP2.04ChemAxon
logS-5.1ALOGPS
pKa (Strongest Acidic)3.88ChemAxon
pKa (Strongest Basic)5.14ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area95.94 Å2ChemAxon
Rotatable Bond Count11ChemAxon
Refractivity124.1 m3·mol-1ChemAxon
Polarizability49.28 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Download (163 KB)
SpectraNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as alpha amino acid esters. These are ester derivatives of alpha amino acids.
KingdomOrganic compounds
Super ClassOrganic acids and derivatives
ClassCarboxylic acids and derivatives
Sub ClassAmino acids, peptides, and analogues
Direct ParentAlpha amino acid esters
Alternative Parents
Substituents
  • Alpha-amino acid ester
  • Phenylpropylamine
  • Aralkylamine
  • Fatty acid ester
  • Fatty acyl
  • Benzenoid
  • Dicarboxylic acid or derivatives
  • Monocyclic benzene moiety
  • Heteroaromatic compound
  • Thiophene
  • Tertiary carboxylic acid amide
  • Tertiary amine
  • Lactam
  • Carboxylic acid ester
  • Carboxamide group
  • Azacycle
  • Organoheterocyclic compound
  • Dialkylthioether
  • Thioether
  • Secondary amine
  • Secondary aliphatic amine
  • Carboxylic acid
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Carbonyl group
  • Amine
  • Aromatic heteromonocyclic compound
Molecular FrameworkAromatic heteromonocyclic compounds
External DescriptorsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Zinc ion binding
Specific Function:
Converts angiotensin I to angiotensin II by release of the terminal His-Leu, this results in an increase of the vasoconstrictor activity of angiotensin. Also able to inactivate bradykinin, a potent vasodilator. Has also a glycosidase activity which releases GPI-anchored proteins from the membrane by cleaving the mannose linkage in the GPI moiety.
Gene Name:
ACE
Uniprot ID:
P12821
Molecular Weight:
149713.675 Da
References
  1. Furuta S, Kiyosawa K, Higuchi M, Kasahara H, Saito H, Shioya H, Oguchi H: Pharmacokinetics of temocapril, an ACE inhibitor with preferential biliary excretion, in patients with impaired liver function. Eur J Clin Pharmacol. 1993;44(4):383-5. [PubMed:8513851 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Proton-dependent oligopeptide secondary active transmembrane transporter activity
Specific Function:
Proton-coupled intake of oligopeptides of 2 to 4 amino acids with a preference for dipeptides. May constitute a major route for the absorption of protein digestion end-products.
Gene Name:
SLC15A1
Uniprot ID:
P46059
Molecular Weight:
78805.265 Da
References
  1. Tsuji A: Transporter-mediated Drug Interactions. Drug Metab Pharmacokinet. 2002;17(4):253-74. [PubMed:15618677 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Sodium-independent organic anion transmembrane transporter activity
Specific Function:
Mediates the Na(+)-independent transport of organic anions such as sulfobromophthalein (BSP) and conjugated (taurocholate) and unconjugated (cholate) bile acids (By similarity). Selectively inhibited by the grapefruit juice component naringin.
Gene Name:
SLCO1A2
Uniprot ID:
P46721
Molecular Weight:
74144.105 Da
References
  1. Ishizuka H, Konno K, Naganuma H, Nishimura K, Kouzuki H, Suzuki H, Stieger B, Meier PJ, Sugiyama Y: Transport of temocaprilat into rat hepatocytes: role of organic anion transporting polypeptide. J Pharmacol Exp Ther. 1998 Oct;287(1):37-42. [PubMed:9765319 ]
Comments
comments powered by Disqus
Drug created on February 19, 2013 17:04 / Updated on August 17, 2016 12:24